{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:33:32Z","timestamp":1780497212885,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA219342"],"award-info":[{"award-number":["R01CA219342"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canlet.2025.217790","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T19:25:31Z","timestamp":1746905131000},"page":"217790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC"],"prefix":"10.1016","volume":"627","author":[{"given":"Yibo","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himadri","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetunde","family":"Makinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-He","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-9914","authenticated-orcid":false,"given":"Jian-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-9443","authenticated-orcid":false,"given":"Yue","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217790_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/03602530902741828","article-title":"Clinical pharmacology and pharmacogenetics of gemcitabine","volume":"41","author":"Wong","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.canlet.2025.217790_bib2","first-page":"14","article-title":"Resistance to gemcitabine in pancreatic ductal adenocarcinoma: a physiopathologic and pharmacologic review","author":"Koltai","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.217790_bib3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.20517\/cdr.2021.148","article-title":"DNA damage and metabolic mechanisms of cancer drug resistance","volume":"5","author":"Tiek","year":"2022","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.canlet.2025.217790_bib4","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.canlet.2025.217790_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216345","article-title":"Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers","volume":"571","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217790_bib6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-022-01126-8","article-title":"Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice","volume":"7","author":"Huo","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.canlet.2025.217790_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2025.217790_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217303","article-title":"The eIF3a translational control axis in the Wnt\/beta-catenin signaling pathway and colon tumorigenesis","volume":"605","author":"Dong","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217790_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-019-0841-1","article-title":"BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia","volume":"14","author":"Zhou","year":"2019","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.canlet.2025.217790_bib10","first-page":"11","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2025.217790_bib11","series-title":"Oncology Letters","article-title":"Role of Bcl-2 on drug resistance in breast cancer polyploidy-induced spindle poisons","author":"Yuan","year":"2020"},{"key":"10.1016\/j.canlet.2025.217790_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216965","article-title":"Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: new cues for cancer chemotherapy","volume":"594","author":"Palominos","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217790_bib13","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.18632\/aging.101591","article-title":"The mitomiR\/Bcl-2 axis affects mitochondrial function and autophagic vacuole formation in senescent endothelial cells","volume":"10","author":"Giuliani","year":"2018","journal-title":"Aging"},{"key":"10.1016\/j.canlet.2025.217790_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00018-010-0597-y","article-title":"Apoptosis and aging: increased resistance to apoptosis enhances the aging process","volume":"68","author":"Salminen","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2025.217790_bib15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10600","article-title":"Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders","volume":"479","author":"Baker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217790_bib16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nm.4324","article-title":"Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment","volume":"23","author":"Jeon","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217790_bib17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cell.2017.02.031","article-title":"Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging","volume":"169","author":"Baar","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217790_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.molcel.2009.02.015","article-title":"From promiscuity to precision: protein phosphatases get a makeover","volume":"33","author":"Virshup","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2025.217790_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/bj3530417","article-title":"Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling","volume":"353","author":"Janssens","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2025.217790_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.03.038","article-title":"Selective PP2A enhancement through biased heterotrimer stabilization","volume":"181","author":"Leonard","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217790_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature05351","article-title":"Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme","volume":"445","author":"Cho","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217790_bib22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41467-023-36693-9","article-title":"Structural mechanism for inhibition of PP2A-B56alpha and oncogenicity by CIP2A","volume":"14","author":"Pavic","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217790_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.trecan.2023.09.001","article-title":"CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response","volume":"10","author":"Nagelli","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2025.217790_bib24","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217790_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbamcr.2018.08.020","article-title":"Targeting PP2A in cancer: combination therapies","volume":"1866","author":"Mazhar","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.canlet.2025.217790_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/10409238.2016.1143913","article-title":"PP2A as a master regulator of the cell cycle","volume":"51","author":"Wlodarchak","year":"2016","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2025.217790_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2021.06.022","article-title":"PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition","volume":"520","author":"Meeusen","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217790_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.trecan.2023.09.001","article-title":"CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response","volume":"10","author":"Nagelli","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2025.217790_bib29","article-title":"From basic science to clinical practice: the role of cancerous inhibitor of protein phosphatase 2A (CIP2A)\/p90 in cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.canlet.2025.217790_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2007.06.034","article-title":"PP2A: unveiling a reluctant tumor suppressor","volume":"130","author":"Mumby","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217790_bib31","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s43018-021-00266-w","article-title":"The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer","volume":"2","author":"Adam","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2025.217790_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112616","article-title":"Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition","volume":"42","author":"Cazzoli","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2025.217790_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31865-5","article-title":"The CIP2A-TOPBP1 complex safeguards chromosomal stability during mitosis","volume":"13","author":"De Marco Zompit","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217790_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217110","article-title":"PP2A B55alpha inhibits epithelial-mesenchymal transition via regulation of Slug expression in non-small cell lung cancer","volume":"598","author":"Singh","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217790_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molcel.2015.08.008","article-title":"ATR plays a direct antiapoptotic role at mitochondria, which is regulated by prolyl isomerase Pin1","volume":"60","author":"Hilton","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2025.217790_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.826576","article-title":"Prolyl isomerization-mediated conformational changes define ATR subcellular compartment-specific functions","volume":"10","author":"Biswas","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2025.217790_bib37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3389\/fcell.2020.00813","article-title":"PP2A regulates phosphorylation-dependent isomerization of cytoplasmic and mitochondrial-associated ATR by Pin1 in DNA damage responses","volume":"8","author":"Makinwa","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2025.217790_bib38","doi-asserted-by":"crossref","first-page":"17726","DOI":"10.18632\/oncotarget.7394","article-title":"14-3-3sigma regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression","volume":"7","author":"Qin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.217790_bib39","article-title":"Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics","volume":"1878","author":"Saifi","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2025.217790_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.307","article-title":"Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy","volume":"4","author":"Hill","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2025.217790_bib41","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1101\/gad.14.16.2060","article-title":"tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c","volume":"14","author":"Wei","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2025.217790_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228679","article-title":"Kinome array profiling of patient-derived pancreatic ductal adenocarcinoma identifies differentially active protein tyrosine kinases","volume":"21","author":"Creeden","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.217790_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2019.04.036","article-title":"BIRC5 is a target for molecular imaging and detection of human pancreatic cancer","volume":"457","author":"Liu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217790_bib44","first-page":"241","article-title":"Comparison of methods for evaluating drug-drug interaction","volume":"2","author":"Zhao","year":"2010","journal-title":"Front. Biosci."},{"key":"10.1016\/j.canlet.2025.217790_bib45","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ncb866","article-title":"BID regulation by p53 contributes to chemosensitivity","volume":"4","author":"Sax","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2025.217790_bib46","first-page":"3909","article-title":"Ataxia-telangiectasia and RAD3-related and ataxia-telangiectasia-mutated proteins in epithelial ovarian carcinoma: their expression and clinical significance","volume":"35","author":"Lee","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2025.217790_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36693-9","article-title":"Structural mechanism for inhibition of PP2A-B56\u03b1 and oncogenicity by CIP2A","volume":"14","author":"Pavic","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217790_bib48","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/1535-7163.MCT-14-0420","article-title":"Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation","volume":"14","author":"Ju","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2025.217790_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217008","article-title":"Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A","volume":"597","author":"Andriani","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217790_bib50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0092-8674(00)81589-5","article-title":"Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors","volume":"94","author":"Luo","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217790_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2121-14-32","article-title":"Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis","volume":"14","author":"Brentnall","year":"2013","journal-title":"BMC Cell Biol."},{"key":"10.1016\/j.canlet.2025.217790_bib52","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/sj.cdd.4400689","article-title":"Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release","volume":"7","author":"Slee","year":"2000","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2025.217790_bib53","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1128\/MCB.00013-08","article-title":"Caspase-2 cleavage of BID is a critical apoptotic signal downstream of endoplasmic reticulum stress","volume":"28","author":"Upton","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.217790_bib54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001813-200207000-00002","article-title":"Selective cytotoxicity of gemcitabine in bladder cancer cell lines","volume":"13","author":"Kilani","year":"2002","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.canlet.2025.217790_bib55","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy1","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217790_bib56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4049\/jimmunol.1900930","article-title":"Tumor microenvironment following gemcitabine treatment favors differentiation of immunosuppressive Ly6Chigh myeloid cells","volume":"204","author":"Wu","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2025.217790_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6357609","article-title":"Inactivation of XPF sensitizes cancer cells to gemcitabine","volume":"2019","author":"George","year":"2019","journal-title":"J. Nucleic Acids"},{"key":"10.1016\/j.canlet.2025.217790_bib58","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","article-title":"Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis","volume":"94","author":"Li","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217790_bib59","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1158\/0008-5472.CAN-15-2119","article-title":"PR55alpha subunit of protein phosphatase 2A supports the tumorigenic and metastatic potential of pancreatic cancer cells by sustaining hyperactive oncogenic signaling","volume":"76","author":"Hein","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217790_bib60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41389-019-0172-9","article-title":"PR55alpha regulatory subunit of PP2A inhibits the MOB1\/LATS cascade and activates YAP in pancreatic cancer cells","volume":"8","author":"Hein","year":"2019","journal-title":"Oncogenesis"},{"key":"10.1016\/j.canlet.2025.217790_bib61","doi-asserted-by":"crossref","first-page":"zcac002","DOI":"10.1093\/narcan\/zcac002","article-title":"PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen","volume":"4","author":"Tinsley","year":"2022","journal-title":"NAR Cancer"},{"key":"10.1016\/j.canlet.2025.217790_bib62","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-018-04425-z","article-title":"Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade","volume":"9","author":"Ho","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217790_bib63","doi-asserted-by":"crossref","first-page":"14831","DOI":"10.18632\/oncotarget.7447","article-title":"CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.217790_bib64","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.molonc.2015.01.002","article-title":"Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer","volume":"9","author":"Chien","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2025.217790_bib65","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1541-7786.MCR-13-0542","article-title":"Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer","volume":"12","author":"Farrell","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217790_bib66","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-16-2299","article-title":"Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial","volume":"23","author":"Chung","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217790_bib67","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/15384047.2015.1040961","article-title":"LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential","volume":"16","author":"Hong","year":"2015","journal-title":"Cancer Biol. Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352500357X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352500357X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T03:51:17Z","timestamp":1778471477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352500357X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":67,"alternative-id":["S030438352500357X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217790","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217790"}}